Volume 33,000,000 shares traded, as of 12.00 Wow!
That's serious volume
Something's afoot! |
This is one of the weirdest situations I can remember. Volume, price level vs NAV, general stuff. All weird. |
Perhaps Edison were wrong on dates? |
Maybe a mixed bag and trying to understand the result. |
It should have read out by now. IP will know what's going on. |
Edison set the expectation that Istesso’s Phase 2b trial for its lead drug Leramistat (MBS2320) in rheumatoid arthritis would read out in H1 2024. The study completed in Jan 2024. The Phase 2 trial in idiopathic pulmonary fibrosis (IPF) is also underway and expected to complete in September 2024.
Unfortunately just a waiting game until Istesso is in a position to annouce results |
Have to ask why the selling and is it related to some entity having a problem and needing to cash out now?
So many things moving all at once. |
Assuming I am reading the rns correctly, it's interesting to see that yesterday, before buyback started at approx 9:08, approx 400k had already been bought.
Also out of a total of approx 6m traded IPGroup bought 940k, suggesting that there are others buying down here. |
Fair comment - but these markets are very unforgiving |
Although you could argue a bad result is already in the price. |
Yep. That's my worry... See earlier posts. |
The Istesso arthritis result is going to be key since this is the biggest holding at 11p per share. |
Looking positive this am |
Useful to determine if any action you take is a speculation or an investment to avoid deluding yourself before you even start. |
There's no way to 2nd guess. Speculation is the name of the game. |
I understand that in fact it's unusual for such a delay. Separately the mechanism of this drug has been tried before (to be fair only a quick read from someone), and not gone anywhere. Obviously I hope that there is nothing wrong and the trial read out is all OK and the drug gets further backing. In which case I also hope for a decent rerate. |
Discount to enav is eye watering. If the arthritis read out is positive this will sky rocket |
undervalued just like peer group - will break out |
I have also topped up, first thing this morning, despite being overweight, and overweight ONT. |
All I remember reading was that results were due during 2024.
Did anything state Summer? |
Bit concerned about the Istesso delay and indeed the quality/novelty of the drug in question. |
IPO has the unloved syndrome for small uk shares. As they deal in small uk shares and all these are unloved hence the low price. It doesnt mean the assets they hold are bad its just the market. I hold IPO/Frontier/Duke/Mercia/Tekcapital and they are all pretty much down, although if you do a calculation on some of thier bigger holdings they all have sum-of-the-parts that are much greater than the share price.
Which ever way you look at IPO its worth much more than the current share price. |
Over 9 million traded in just over the hour. |
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Hot Features
Premium
